Deutsche Bank AG Has $1.06 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Deutsche Bank AG boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 50.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 133,886 shares of the company’s stock after purchasing an additional 45,066 shares during the quarter. Deutsche Bank AG’s holdings in Amneal Pharmaceuticals were worth $1,060,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth about $81,000. Straightline Group LLC acquired a new stake in Amneal Pharmaceuticals during the fourth quarter worth approximately $92,000. Brevan Howard Capital Management LP acquired a new stake in Amneal Pharmaceuticals during the fourth quarter worth approximately $107,000. Cibc World Markets Corp bought a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth approximately $118,000. Finally, Janney Montgomery Scott LLC acquired a new position in shares of Amneal Pharmaceuticals in the fourth quarter valued at approximately $121,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on AMRX shares. Wall Street Zen cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, May 13th. Barclays lifted their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the company from $9.00 to $12.00 in a research note on Monday, February 24th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals has an average rating of “Buy” and an average price target of $11.50.

Insiders Place Their Bets

In other news, Director Gautam Patel sold 80,000 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total transaction of $712,000.00. Following the completion of the transaction, the director now owns 1,808,886 shares of the company’s stock, valued at approximately $16,099,085.40. This trade represents a 4.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the transaction, the insider now owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. This trade represents a 9.33% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock opened at $7.16 on Monday. The firm has a market cap of $2.24 billion, a PE ratio of -10.53 and a beta of 1.17. The stock’s fifty day moving average price is $7.62 and its two-hundred day moving average price is $8.05. Amneal Pharmaceuticals, Inc. has a one year low of $6.29 and a one year high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.05. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The business had revenue of $695.42 million during the quarter, compared to analysts’ expectations of $714.78 million. Sell-side analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.